Fredun Pharmaceuticals Limited Q3 FY26 earnings call summary

Earnings call of 12 Feb 2026, summarised by AI from the filing.

Q3 FY26 total income ₹160.92 cr (+57% YoY), EBITDA ₹26.34 cr (+99% YoY); vintage business guided to grow 12-18% YoY for next 5-7 years.

Key takeaways

1. Change Pet biscuits production started in Q3; revenues to show from this quarter.
2. Driver New-age brands (mobility, pet care, dermaceutics) growing 20-25% YoY, driving growth.
3. Risk Cannot sustain same percentage growth as numbers get larger.

Original filing on BSE

Fredun Pharmaceuticals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (13 Aug 2026)
• Q4 FY26: Earnings call (10 Jun 2026)
• Q3 FY26: Earnings call (12 Feb 2026)
• Q2 FY26: Earnings call (11 Nov 2025)
• Q1 FY26: Earnings call (1 Aug 2025)
• Other events: Call transcript (6 Jun 2026), Strategy deck (10 Jun 2025), Strategy deck (10 Jun 2025)